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Background: Gastric cancer remains a serious health concern worldwide. Patients would greatly benefit from the
discovery of new biomarkers that predict outcome more accurately and allow better treatment and follow-up
decisions. Here, we used a retrospective, observational study to assess the expression and prognostic value of the
transcription factors SOX2 and CDX2 in gastric cancer.
Methods: SOX2, CDX2, MUC5AC and MUC2 expression were assessed in 201 gastric tumors by immunohistochemistry.
SOX2 and CDX2 expression were crossed with clinicopathological and follow-up data to determine their impact on
tumor behavior and outcome. Moreover, SOX2 locus copy number status was assessed by FISH (N = 21) and Copy
Number Variation Assay (N = 62).
Results: SOX2 was expressed in 52% of the gastric tumors and was significantly associated with male gender, T stage
and N stage. Moreover, SOX2 expression predicted poorer patient survival, and the combination with CDX2 defined
two molecular phenotypes, SOX2+CDX2− versus SOX2−CDX2+, that predict the worst and the best long-term patients’
outcome. These profiles combined with clinicopathological parameters stratify the prognosis of patients with intestinal
and expanding tumors and in those without signs of venous invasion. Finally, SOX2 locus copy number gains were found
in 93% of the samples reaching the amplification threshold in 14% and significantly associating with protein expression.
Conclusions: We showed, for the first time, that SOX2 combined with CDX2 expression profile in gastric cancer
segregate patients into different prognostic groups, complementing the clinicopathological information. We further
demonstrate a molecular mechanism for SOX2 expression in a subset of gastric cancer cases.
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Gastric cancer is one of the most commonly diagnosed
cancers and now the third leading cause of cancer-related
deaths in the world [1]. Laurén classification divides
gastric cancer into two main histological types: intestinal
and diffuse [2]. They present distinct morphological,
clinical and epidemiological features and are thought to
develop from the activation of independent molecular* Correspondence: ralmeida@ipatimup.pt
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unless otherwise stated.mechanisms. Epidemiological data shows that, in most
cases, gastric cancer does not arise de novo from the
normal gastric epithelium, but rather results from a
multistep process, through successive genetic and epigenetic
alterations in multiple genes. Contrary to the diffuse
type, for which predisposing lesions are not well established,
the succession of events leading to gastric cancer of
the intestinal type is well described. According to the
Correa’s cascade, it develops in a stepwise manner,
usually initiated by an inflammatory process triggered by
Helicobacter pylori, which may progress to multifocal
atrophic gastritis, intestinal metaplasia (IM), dysplasia and
finally adenocarcinoma [3].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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cancer incidence globally, the expansion and aging of the
World’s population forecasts an increase in the number of
cases and, despite the latest developments in diagnosis and
treatment, the prognosis of gastric cancer patients remains
poor. This translates into a 5-year survival rate of no more
than 25%, in Europe [4]. Most gastric cancer patients have
advanced disease at diagnosis for whom the only option of
cure relies on complete surgical removal of the tumor, with
extensive lymph node dissection that can be complemented
by the administration of neoadjuvant or adjuvant chemo-
therapy [5]. The most important prognostic factor influen-
cing survival as well as treatment choice is the TNM stage.
However, an additional layer of complexity stems from the
observation that patients with the same staging often show
a different clinical evolution, highlighting the heterogeneity
of gastric cancer [6]. This suggests that unique intrinsic
biological properties of these tumors may significantly
impact their aggressive potential. Therefore, there is still a
pressing need to discover additional prognostic biomarkers
to predict outcome more accurately and, as a result, to help
make better informed treatment decisions with respect to
therapy. As tumors that are more differentiated generally
behave in a less aggressive fashion, we questioned the
relevance of two differentiation markers, SOX2 and CDX2,
for the biological behavior of gastric cancers. These markers
are differentially expressed along the chain of events that
lead to gastric cancer and are closely associated with gastric
and intestinal differentiation, respectively [7].
CDX2 is an intestine-specific homeobox transcription
factor whose function ensures the development and
maintenance of intestinal differentiation in the gut
and ectopic sites, which was well established in animal
models [8,9]. It is widely known that CDX2 is expressed in
human intestinal metaplasia of the stomach and esophagus
[10]. It was shown to be also expressed in dysplasia
thus reinforcing its role as a biomarker of progression in
the preneoplastic stages of gastric carcinogenesis [11].
SOX2 is a member of the SOX (SRY-related HMG
Box) family of transcription factors, encoded by a highly
conserved, single exon gene. SOX2 plays diverse roles
throughout development and cell differentiation, first
orchestrating the mammalian embryogenesis [12], and
later contributing to the normal morphogenesis and
homeostasis of the foregut-derived epithelia of the
esophagus, lung and trachea [13]. In adulthood, SOX2 is
expressed in a variety of tissues, namely in the squamous
epithelium lining the esophagus and the glandular
epithelium of the stomach. It has been shown, in
mice, that Sox2 expression contributes to all the cell
lineages normally found in the stomach, suggesting an
important contribution for gastric differentiation [14].
In addition, abnormal expression of SOX2 has been
observed in tumors of the brain, breast, lung and esophagus[15-17]. However, in the gastric cancer context, its role
remains puzzling and needs further clarification [18-20].
Furthermore, its interplay with CDX2 remains unexplored.
Our aim was to analyze the clinical relevance of SOX2
and CDX2 expression in gastric cancer biology. The results
obtained show that their expression in the primary tumors
has a relevant prognostic value for gastric cancer patients.
Methods
Human tissues and DNA samples
Two hundred and one cases of formalin-fixed paraffin-
embedded (FFPE) samples from patients with gastric
adenocarcinoma undergoing surgery at Centro Hospitalar
S. João, Porto, Portugal between 1988 and 2010 were
studied. Cases selected were those with available paraffin-
embedded material, clinicopathological and follow-up data
obtained from the Pathology and Surgical Departments of
Centro Hospitalar S. João. From those, sixty-seven
samples were provided as a tissue microarray (TMA),
with 2 replicate cores of each sample, from the Tumor
and Tissue Biobank of the same Pathology Department.
Tumour genomic DNA (gDNA) was obtained from 62
cases included on the TMA. gDNA was also extracted
from FFPE samples of two normal gastric mucosas using
the Genomic DNA Purification Kit (Citomed, Lisbon,
Portugal), and used as controls. All samples from the
Biobank were obtained with informed consent from
the patients. The use of retrospective samples from which
informed consent cannot be obtained is authorized
for research studies by the Portuguese law. This study was
approved by the ethics committee of Centro Hospitalar
S. João.
Immunohistochemistry
FFPE tissue sections with 4 μm from surgical specimens
and TMA were subjected to immunohistochemistry
for SOX2, CDX2, MUC5AC and MUC2, following
standard methodologies. Briefly, after deparaffination
and rehydration, antigen retrieval was performed in a
IHC-Tek Epitope Retrieval Steamer Set (IHC World,
Woodstock, MD, USA), for 40 minutes with 10 mM
citrate buffer, pH 6.0 (CDX2) or 10 mM, pH 8.0 EDTA
(SOX2). Desialylation was performed for MUC2 detection,
with 0.1 U/mL of Neuraminidase from Clostridium
perfringes type VI (Sigma-Aldrich, St. Louis, MO, USA) in
sodium acetate buffer pH 5.5 for 2h at 37°C. Endogenous
peroxidase was blocked with 3% hydrogen peroxide in
methanol for 10min. Incubation with primary antibodies
for CDX2 (1:50 dilution, CDX2-88 clone, Biogenex, San
Ramon, CA, USA), MUC5AC (1:10 dilution, CLH2 clone)
and MUC2 (1:10 dilution, PMH1 clone) was performed
overnight, at 4°C. Sections were then incubated with
a biotin-labeled rabbit anti-mouse secondary antibody,
followed by the avidin/biotin-peroxidase detection system
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USA). For SOX2 staining, incubation with the primary anti-
body (1:50 dilution, SP76 clone, Cell Marque, Rockling, CA,
USA) was performed for 1h at RT and detection was done
using the Dako REAL™ Envision™ Detection System
Peroxidase/DAB + (DAKO, Glostrup, Denmark) according
to the manufacturer’s instructions. Detection of expression
was performed with 3,3′-diaminobenzidine (DAB) (Sigma,
St. Louis, MO, USA) tissue sections were counterstained
with Gill’s haematoxylin (Leica Microsystems, Amersham,
Bucks, UK), dehydrated, clarified and mounted. Normal
gastric mucosa was used as a positive control for SOX2
and MUC5AC expression and normal colonic mucosa
was used as a positive control for CDX2 and MUC2
expression. Cases were considered positive when more
than 5% of the cells were stained with each antibody with
consensus of three observers (VC; LD and RA).
Fluorescence In Situ Hybridization (FISH)
FISH was used to assess SOX2 amplification status in 21
samples, using a 2-color assay as described by Bass et al
[17]. A probe spanning the locus 3q26.33 (BAC clone
CTD-2348H10) was used to determine SOX2 copy number
and was compared with a reference probe hybridizing to
3p22.3-3p22.2 (BAC clone RP11-286G5), purchased from
Invitrogen (Carlsbad, CA, USA). The target probe was
labelled with digoxigenin (DIG-11-UTP, Roche, Mannheim,
Germany) and detected with an anti-digoxigenin–fluorescein
antibody (Roche Diagnostics GMbH, Mannheim, Germany)
and the reference probe was labelled with biotin (BioPrime®
DNA labelling System, Invitrogen, Carlsbad, CA, USA) and
detected with a CY3-Avidin antibody (Jackson Immunore-
search Lab, West Grove, USA).
Four μm slides from each gastric adenocarcinoma sample
were deparaffinised, rehydrated and placed in a pre-heated
solution of NaSCN 1M at 80°C for 10 min. Samples were
digested with 6mg/ml pepsin (Sigma-Aldrich, St. Louis,
MO, USA) in HCl 0.02N, pH 2 for 30min at 37°C. Probe
mixture in 50% formamide in 2× SSC was codenatured
with nuclear DNA at 94°C for 3min. Hybridisation was car-
ried out for 30h at 37°C. Nuclei were counterstained with
DAPI-Vectashield mounting solution (Vector, Burlingame,
USA). For each case, a minimum of 67 cells were analysed
in a fluorescence microscope (Zeiss Z1 Axio) and images
were acquired with a 1000× magnification, using a Zeiss
Axio cam MRm and the Axiovision Rel. 4.8 software. The
ratio between the number of SOX2 and the reference probe
signals was calculated for each cell individually and the
average of the ratios was determined for each case. Gene
amplification was considered whenever the average was ≥2.
Copy Number Variation (CNV) Assays
The CNV assay was performed using a specific TaqMan®
Copy Number Assay (Applied Biosystems, Foster City,CA, USA) following the manufacturer’s instructions.
Briefly, multiplex PCRs for SOX2 (target) and Rnase
P (endogenous control) were performed on an ABI
Prism7500 Fast Real-time PCR system using the software
v2.0 (Applied Biosystems, Foster City, CA, USA). Twenty
nanograms of gDNA and a non-template control were
analyzed in quadruplicate. Normal gastric mucosa samples
were used as calibrators. Quantification of SOX2 gene
copy number was done using the ΔΔCt method and data
analysis was performed by the CopyCaller software
v2.0 (Applied Biosystems, Foster City, CA, USA). Gene
amplification was defined whenever the gene copy
number was 2-fold greater than that of the normal
gastric mucosa. Fold increase between 1.5 and 2 was
considered copy number gain.
Statistical analysis
The chi-square test was used to assess the significance
of differences in clinicopathological characteristics
across categories of SOX2 and CDX2 expression, except
with age, where the significance of differences in means
was calculated using the T-test. Patients’ overall survival
was calculated using the Kaplan-Meier method and the
significance of differences between crude survival curves
was tested by the log-rank test. Cox proportional haz-
ards model was used to calculate univariate and multi-
variate hazard ratios. Median follow-up time for
surviving patients was 62 months. The 5- and 10-year
survival rate was estimated using the life-table method.
Differences were considered statistical significant when-
ever the p values were <0.05. Analyses were performed
using SPSS software v21.0 (Chicago, IL, USA) and Stata
v11 (College Station, TX, USA).
Results
SOX2 expression in gastric carcinomas
Clinicopathological features of the 201 gastric cancer
cases, as well as the expression profiles of SOX2, CDX2,
MUC2 and MUC5AC are summarized in Table 1.
Nuclear SOX2 expression was found in 52% (104/201) of
gastric carcinomas and the expression was heterogeneous
among and within the tumors (Figure 1A, B and C). In
13% (18/134) of the cases SOX2 expression was higher at
the invasive front (Figure 1D and E) (this evaluation was
only performed in cases not included in the TMA, where
this assessment was not possible).
Next, we assessed whether SOX2 expression correlated
with clinicopathological features of the cases. This
analysis revealed that SOX2 expression was significantly
associated with male gender (p = 0.02), with higher T stage
(p = 0.03) and with presence of regional lymph node
metastases (N stage) (p = 0.03). The other clinicopatholog-
ical parameters, which included age, TNM stage, tumor
clearance at resection margins (R category), vascular
Table 1 Summary of the clinicopathological parameters of gastric cancer according to the expression of SOX2 and CDX2
SOX2 CDX2
Negative Positive Negative Positive
N % N % p N % N % p
Age, years1
Mean ± SD 65.8 ± 12.7 63.4 ± 13.5 0.2 64.1 ± 13.6 65.2 ± 12.6 0.6
Median (Range) 69 (34-85) 66.5 (24-89) 69 (24-89) 67 (36-89)
Sex1
Male 52 41.9 72 58.1
0.02
75 60.5 49 39.5
0.1
Female 45 58.4 32 41.6 38 49.4 39 50.6
TNM stage2
I/II 35 54.7 29 45.3
0.09
26 40.6 38 59.4
0.002
III/IV 59 44.7 73 55.3 83 62.9 49 37.1
T stage3
T1/T2 22 62.9 13 37.1
0.03
13 37.1 22 62.9
0.007
T3/T4 75 45.5 90 54.5 99 60.0 66 40.0
N stage1
N0 28 62.2 17 37.8
0.03
20 44.4 25 55.6
0.07
N+ 69 44.2 87 55.8 93 59.6 63 40.4
Margins4
R0 85 47.5 94 52.5
0.5
98 54.7 81 45.3
0.2
R1 11 55.0 9 45.0 14 70.0 6 30.0
Vascular invasion4
Negative 39 55.7 31 44.3
0.1
37 52.9 33 47.1
0.5
Positive 57 44.2 72 55.8 75 58.1 54 41.9
Láuren5
Intestinal 44 49.4 45 50.6
0.9
45 50.6 44 49.4
0.3Diffuse 20 48.8 21 51.2 26 63.4 15 36.6
Unclassified 31 46.3 36 53.7 40 59.7 27 40.3
Ming6
Expansive 32 53.3 28 46.7
0.5
28 46.7 32 53.3
0.1Infiltrative 60 45.8 71 54.2 81 61.8 50 38.2
Unclassified 2 66.7 1 33.3 1 33.3 2 66.7
SOX21
Negative 58 59.8 39 40.2
0.3
Positive 55 52.9 49 47.1
CDX21
Negative 58 51.3 55 48.7
0.3
Positive 39 44.3 49 55.7
MUC5AC1
Negative 39 44.8 48 55.2
0.4
42 48.3 45 51.7
0.05
Positive 58 51.3 55 48.7 70 61.9 43 38.1
MUC21
Negative 69 48.6 73 51.4
0.9
84 52.2 58 40.8
0.1
Positive 27 48.2 29 51.8 26 46.4 30 53.6
1N = 201; 2N = 196; 3N = 200; 4N = 199; 5N = 197; 6N = 194.
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Figure 1 SOX2 protein expression in gastric carcinomas, detected by immunohistochemistry. (A) Heterogeneity of SOX2 expression in
gastric tumors. Within the same tumor sample, areas with high levels of SOX2 are observed (B) in close proximity to areas with lower expression
levels of SOX2 (C). (D, E) SOX2 expression at the invasive front of tumors.
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were not significantly associated with SOX2 expression
(Table 1).
Since SOX2 is associated with gastric differentiation
[14] we studied whether this was maintained in cancer,
using MUC5AC as a gastric marker. However, no associ-
ation was found between SOX2 and MUC5AC expression.
Likewise, no reverse association was found between
SOX2 and CDX2/MUC2 (used as markers of intestinal dif-
ferentiation). Of note, CDX2 expression was significantly
associated with a lower TNM stage (p = 0.002) and
with a lower T stage (p = 0.007). Furthermore, although
not statistically significant, there was a trend towards
an inverse relationship between CDX2 and MUC5AC
(p = 0.05).
Survival analysis
The 5-year overall survival, based on the follow-up of
199 patients, was 35% (Additional file 1: Figure S1). We
next observed that SOX2 expression in the tumors was
associated, in univariate analysis, with an overall poorer
survival (p = 0.02), stratifying the patients into two
prognostic groups (Figure 2A), with a 5-year survival
of 45% for patients with SOX2- tumors versus 26%
for patients with SOX2+ tumors. On the contrary,
CDX2 expression associated with an overall improved
survival, although the difference did not reach significance
(data not shown).
Based upon the association of SOX2 and CDX2
with worse and better survival as well as more and less
aggressive clinicopathological features, respectively, wefurther studied patients’ outcome according to the molecu-
lar phenotypes defined by both proteins. Four groups of
patients could be defined (Additional file 1: Figure S2) of
which the one with the best survival had tumors negative
for SOX2 and positive for CDX2 (SOX2-/CDX2+),
whereas the survival was the lowest in patients harboring
tumors with the reverse profile, positive for SOX2
and negative for CDX2 (SOX2+/CDX2-) (p = 0.01)
(Additional file 1: Figure S2 and Figure 2B). The cases with
expression of both SOX2 and CDX2 or without expression
of either marker exhibited a similar and intermediate
survival (Additional file 1: Figure S2). The SOX2-/CDX2+
and SOX2+/CDX2- molecular phenotypes, compared with
SOX2 alone, predict very similar survival rates at 5-years
(49% vs 26% and 45% vs 26%, respectively). However, the
predicted 10-year survival rate based on SOX2 expression
alone is 34% (SOX2-) vs 22% (SOX2+) whereas, using
the SOX2/CDX2 molecular phenotypes, it becomes 41%
(SOX2-/CDX2+) vs 14% (SOX2+/CDX2-).
We further explored the impact in patients’ survival of the
molecular phenotypes defined by SOX2+ vs SOX2-, CDX2+
vs CDX2- and SOX2-/CDX2+ versus SOX2+/CDX2-
stratified according to clinicopathological parameters.
In this case, plotting survival according to either SOX2 or
CDX2 status alone yielded significant prognostic differences
for the former, in some of the parameters (intestinal- and
expanding-type tumors) and no differences for CDX2 alone
(Additional file 1: Figures S3 and S4). Results from Cox
proportional model are presented in Additional file 1: Table
S1. Once more, the use of the combined expression of
SOX2 and CDX2 refined the previous results (Figure 3).
Figure 2 Kaplan-Meier curves showing the probability of overall survival for patients with gastric cancer according to SOX2 expression
(A) and according to the molecular phenotypes SOX2−/CDX2+ and SOX2+/CDX2− (B).
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outcome of patients with intestinal (p = 0.005) and
expanding (p = 0.002) tumors, with hazard ratios of
3.18 and 4.84, respectively, and of those without signs of
venous invasion (p = 0.009), presenting a hazard ratio of
3.84. Although borderline non-significant, a similar trend
was observed in patients without lymph node metastases
(p = 0.08) (Figure 3). Hazard ratios and 95% confidenceFigure 3 Kaplan-Meier curves showing the probability of overall surv
phenotypes SOX2−/CDX2+ and SOX2+/CDX2− stratified according to c
classification (B), venous invasion (C) and lymph node metastases (D)intervals for all groups are presented in detail in Table 2
and remain significant after adjusting for age and gender
in a multivariate analysis.
SOX2 amplification
Considering that gene amplification is a tumor-specific
event during malignant transformation, and that SOX2
locus is subjected to this alteration in other tumors,ival for patients with gastric cancer according to the molecular
linicopathological parameters: Laurén classification (A), Ming
.
Table 2 Cox Proportional Hazards Models of survival as a
function of the molecular phenotypes (SOX2+/CDX2- vs
SOX2-/CDX2+) for each clinicopathological parameter
Parameter Hazard ratio
(95% CI)
Unadjusted P Adjusteda P
Overall 1.95 (1.15-3.31) 0.01 1.90 (1.10-3.28) 0.02
Laurén classification
Intestinal-type 3.18 (1.33-7.58) 0.009 2.93 (1.21-7.10) 0.02
Diffuse-type 1.35 (0.35-5.17) 0.7
Unclassified 1.34 (0.60-3.02) 0.5
Ming classification
Expanding 4.84 (1.64-14.29) 0.004 4.53 (1.29-15.85) 0.02
Infiltrative 1.13 (0.60-2.13) 0.7
Vascular invasion
Negative 3.84 (1.30-11.35) 0.02 3.82 (1.29-11.40) 0.02
Positive 1.10 (0.60-2.02) 0.8
N stage
N0 2.96 (0.82-10.65) 0.1 3.98 (0.72-21.83) 0.1
N+ 1.29 (0.72-2.30) 0.4
Abbreviation: CI confidence interval.
a Adjusted for age and gender (Multivariate analysis using the Cox
regression model).
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that SOX2 amplification could explain its expression
and heterogeneity, both within and among gastric
tumors. Supporting this hypothesis, a survey performed
on the Oncomine database showed that SOX2 ranked
among the top 10% genes with copy number gains in
gastric cancer (Additional file 1: Figure S5).
Based on immunohistochemistry data, we selected
14 cases with SOX2 expression and 7 negative cases
to analyse by 2-color FISH assay. We observed that
SOX2 was amplified in 14% (2/14) of the cases with
expression and in none of the cases without expression
(0/7). A representative positive case both for SOX2
expression and amplification is shown in Figure 4A
and B. A case with SOX2 expression but no amplification
is shown in Figure 4C and D. Moreover, the FISH
analysis demonstrated the presence of a high degree
of copy number gain and heterogeneity within tumors,
observed not only with the target probe for SOX2 locus
but also with the reference probe, located to the 3p arm
(Additional file 1: Figure S6).
To clarify the frequency of SOX2 locus copy number
alterations in gastric cancer, we performed a copy-number
PCR using gDNA from 62 gastric cancer cases, using a
RNAse P probe located in chromosome 14 as reference.
The majority of the samples (93%) presented some
degree of SOX2 copy number variation, ranging from 3
to 9 copies (Figure 4E). A significant positive associationbetween copy number gain and SOX2 expression (p < 0.05)
was observed (Figure 4F).
Discussion
Gastric cancer is a disease with multiple outcomes that
cannot be predicted by clinicopathological features
alone [6]. Consequently, the identification of molecular
biomarkers that may allow further outcome stratification
and treatment decisions is of critical importance.
In this study we characterized the expression of the
transcription factor SOX2 in gastric cancer and related
it with clinicopathological features and differentiation
markers namely MUC5AC (gastric marker) and CDX2 and
MUC2 (intestinal markers). This led to the identification
of two different prognostic groups, based on SOX2
expression, which could be further refined by taking into
account the combined expression with CDX2. Finally, we
unraveled the heterogeneity of SOX2 locus and chromo-
some 3 copy number in gastric cancer, demonstrating an
association between increased copy number and SOX2
protein expression.
A key finding of this study was the observation that
SOX2 expression alone, and further refined by the
combination with CDX2, allows the stratification of
patients into subgroups with significantly different
clinical outcomes. Moreover, when we combined these
molecular profiles with clinicopathological data, it became
evident that the SOX2+/CDX2− profile associated with a
poorer prognosis, within subsets of tumors that in general
have a better prognosis: intestinal-type, expanding-type
and with no signs of venous invasion [21,22]. Although
not statistically significant, the same tendency was
observed for tumors presenting without lymph node
metastases. These molecular profiles indicate a different
biological behavior of the tumor most likely due to disease
progression or treatment resistance and may be used to
instruct more effective therapy or follow-up schedules.
Notably, as lymph node metastasis is one of the main
risk factors for gastric cancer recurrence, after an R0
surgery, all patients presenting lymph node metastases
receive adjuvant therapy [23]. However, our results show
that patients without this risk factor, and thus not treated,
present a strikingly worse outcome when the tumor
presents with a SOX2+/CDX2− molecular profile. This
puts forward the hypothesis that, within N0 tumors,
patients within this molecular subgroup would likely
benefit from adjuvant therapy. Nevertheless, these observa-
tions require validation in larger cohorts and it would also
be very informative to add clinical information regarding
patient treatment.
SOX2 also emerges as a potential target for novel
therapeutic interventions. Although transcription factors
are not classical drug targets, approaches to SOX2-targeted
therapy are already being addressed in breast cancer. In a
Figure 4 Gastric cancer cases with SOX2 protein expression (A and C) can present with or without SOX2 amplification (B and D, respectively)
determined by FISH. Green labeled probes target SOX2, whereas red labeled probes target the 3p arm. Nuclei are stained with DAPI (blue). (E) Sixty-two
gDNA gastric cancer samples were assessed for SOX2 copy number status and compared to normal gastric mucosa (calibrator). (F) SOX2 copy number
was significantly associated with protein expression, determined by IHC (p< 0.05).
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zinc-finger-based artificial transcription factors approach,
resulting in its highly specific, potent and long lasting
down-regulation, translating into an attenuated tumori-
genicity, both in vitro and in vivo [24].
Apart from the impact of SOX2 expression on patients’
survival, it is also associated with other clinicopathological
features, namely male gender, more advanced T stage and
venous invasion. The first is difficult to interpret but thelast two suggest that SOX2 might have a role in the
cellular properties that influence motility and invasion.
Concordantly, in 13% of the cases SOX2 expression was
higher in the tumor invasive front. This is in accordance
with a study performed in a gastric cancer cell line [25],
and other studies using different tumor models, namely
gliomas, colorectal cancer and melanomas, where SOX2
was associated with disease progression and poor clinical
outcome [26-28]. In the gastric cancer context, however,
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a tumor suppressor function, based on in vitro studies
[19] and loss of expression [18], not confirmed in
more recent ones [20,25], including ours.
Interestingly, SOX2 has been coined as a lineage-survival
oncogene in different tumor models, proposing that cell
lineage–specific genes involved in development can become
dysregulated in cancer and promote tumorigenesis [17,29].
SOX2 encodes a key stem cell transcription factor and
additionally it is involved in the foregut morphogenesis
[13]. In this study we did not find an association between
SOX2 and gastric differentiation, evaluated by MUC5AC
expression, which was previously described in gastric
premalignant lesions and cancer [30,31]. This observation,
combined with the association with more aggressive
clinicopathological features and worse survival, led us to
hypothesize that, in this context, SOX2 may have other
archetypal functions, associated to stemness features. These
features would facilitate key processes such as epithelial to
mesenchymal transition (EMT) and tumor spreading. This
hypothesis is supported by numerous reports showing
that SOX2 drives EMT in several cancer models, by
upregulating several keystone proteins of this process,
namely Snail, Slug and Twist [27,32].
Another key observation in this study was the heterogen-
eity of SOX2 expression levels within and among cancers.
Since SOX2 is a target of amplification in different tumors,
we hypothesized that this genetic alteration, frequently
associated with tumor progression, could explain not only
the expression but also the heterogeneity of SOX2. The
region 3q26-27, that encompasses SOX2 locus, is a target of
copy number gains in 18%-24% of gastric primary tumors
[33]. Furthermore, copy number gain was also frequently
detected in the long arm of chromosome 3 in gastric cell
lines [34]. From the FISH results, combined with the
copy-number PCR, which was performed in a larger
set of gastric cancer cases, we can conclude that
SOX2 locus copy number gain is a frequent event in
gastric cancer. Although genomic instability is found
in most solid tumors and also in gastric cancer [35] it was
surprising to find that more than 90% of the tumors
present copy number gain of this locus. Notwithstanding,
amplification of this gene, determined by FISH, could only
be defined in 14% of the cases. Copy number gain is most
likely not the sole mechanism associated with SOX2
expression since there are SOX2 positive cases without
copy number gain and also the reverse. This was also
observed in other tumor models, namely squamous
carcinoma of the lung and gliomas [17,26]. It remains to
be confirmed whether, in the gastric context, SOX2 is the
only target of copy number gain or amplification in this
region. In fact, there are known oncogenes located in
this genomic region [36] that might also be targets of
copy number alterations and impact the biologicalbehavior of the tumors. It has recently been shown
that co-amplification of SOX2 and PRKCI contributes to
the aggressive behavior of lung squamous cell carcinoma,
by promoting a stem-like phenotype through activation of
the Hedgehog signaling [37].
Conclusions
In conclusion, we show for the first time that SOX2
together with CDX2 expression profiles in gastric
cancer contributes to segregate patients into different
prognostic groups, complementing the clinicopathological
information. Moreover, we show that SOX2 locus copy
number gain is a frequent event in gastric cancer, explaining
SOX2 protein expression and also pinpointing a genomic
region frequently subjected to genomic instability.
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